Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
InfectologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Archivos de bronconeumologia
- Publicado em
- 2 dez 2024
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
Adrián Sánchez-Montalvá, José Antonio Caminero, Mª Remedio Guna, Teresa Rodrígo Sanz, Ramón Rabuñal, Joan-Pau Millet, José Antonio Gullón-Blanco, Luís Anibarro, Guillermo Pérez-Mendoza, Juan Francisco Medina et al.
Descritores MeSH
- Tuberculosis, Multidrug-Resistant
- Antitubercular Agents
- Mycobacterium tuberculosis
- Societies, Medical
- Rifampin
- Spain
- Tuberculosis, Pulmonary
- Pulmonary Medicine
- Nucleic Acid Amplification Techniques
- Infectious Disease Medicine
Veja também
Estudos relacionados
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
- A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis